Markets Big Reversal… And A Potential Small Cap Comeback 4/4/24

4 Apr 2024 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Podcast Episode Summary: CNBC's "Fast Money" - Markets Big Reversal and A Potential Small Cap Comeback (4/4/24)

Episode Overview In this episode of CNBC's "Fast Money," hosted by Melissa Lee, the roundtable of traders discusses a significant sell-off in major stock indices, the implications of the Federal Reserve's stance on interest rates, and the potential for a small cap market resurgence. The episode delves into various sectors, providing insights on stocks such as Meta and developments in the GLP-1 pharmaceutical space.

---

Key Themes

  1. Market Sell-Off
  2. Late-Day Market Reaction: Major indices, including the Dow, NASDAQ, and S&P 500, experienced sharp declines, attributed to:
  3. Geopolitical Tensions: Increased tensions between Israel and Iran leading to a surge in oil prices.
  4. Federal Reserve Concerns: Comments from Minneapolis Fed President Neil Kashkari indicating a potential delay in rate cuts, raising fears of prolonged inflation concerns.
  5. Market Movement:
  6. The Dow dropped by 530 points, marking its largest loss since March 2023.
  7. Intraday volatility saw a notable sell-off after earlier gains.
  1. Federal Reserve's Influence
  2. Fed's Stance: Multiple Fed officials echoed concerns about inflation and growth, suggesting that rate cuts might not happen as early as previously thought.
  3. Market Sentiment: The traders expressed uncertainty over the Fed's trajectory, emphasizing the impacts of rising yields and the potential for stagflation.
  1. Sector Analysis
  2. Technology and Big Tech:
  3. Notable mention of NVIDIA, whose stock volatility was highlighted as a significant market mover.
  4. Observations that despite tech's historical resilience during downturns, recent performance indicated weakness across tech and semiconductor sectors.
  5. Energy Sector: Discussion around rising crude oil prices and their effects on energy stocks and broader market volatility.
  1. Small Cap Potential
  2. Small Cap Recovery: The episode featured insights from Greg Torto of Goldman Sachs Asset Management, who highlighted:
  3. Consumer Spending: A bullish outlook on small-cap stocks, particularly in the restaurant sector (e.g., Shake Shack and Kava) due to efficient management and recovery strategies.
  4. Selectivity in Investments: Emphasis on choosing profitable companies within small caps, avoiding those with poor fundamentals or excessive debt.
  1. GLP-1 Drugs and New Applications
  2. Pharmaceutical Advances:
  3. Discussion about GLP-1 drugs, particularly in relation to new studies suggesting their potential for treating Parkinson's disease, alongside existing uses for obesity and diabetes treatment.
  4. Dr. Kavita Patel provided insights into the recent studies, focusing on the implications for companies like Novo Nordisk and Eli Lilly.

---

Key Takeaways

  • Market Volatility: The traders believe that the recent market sell-off reflects deeper anxieties regarding the Fed's approach to inflation and economic growth.
  • Investment Strategy: Caution is advised, particularly in sectors that traditionally perform well during downturns, as rising geopolitical tensions and inflation pressures challenge the market.
  • Small Caps as an Opportunity: Despite overall market fears, certain small-cap stocks are poised for recovery, with a focus on consumer-driven sectors.
  • Healthcare Innovations: The promising developments in GLP-1 research highlight the evolving landscape of pharmaceuticals and the potential for new drug markets.

---

Conclusion As the Fast Money roundtable navigates the complexities of current market dynamics, they emphasize the importance of adapting investment strategies in response to economic indicators and geopolitical events. With discussions centered around both short-term challenges and long-term opportunities, particularly in small-cap stocks, investors are encouraged to remain vigilant and informed.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Live from the Nasdaq MarketSite in the heart of New York City's Times Square. This is Fast Money. Here's what's on tap tonight. A late-day market sell-off. Major indices all taking a sharp leg lower late in the session as tensions between Israel and Iran ramp up. The headlines have sent stocks tumbling and what they mean for your money. Plus, Meta managing to hold on to gains after touching a new record high earlier in the session. Shares of the social media giant has added more than$430 billion in market cap just this year. Can the momentum continue? We'll debate that. And later, the next big thing for GLP-1 drugs.

0:32New studies seeing hopeful signs for treating Parkinson's disease, what it could signal for the space and the stocks poised for gains. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Karen Feinemann, Dan Nathan and Guy Adami. We start off with that late day sell-off that took markets sharply lower. The Dow ending the day down 530 points, posting its biggest one-day loss since March of last year. It had been up nearly 300 points at its highs. The NASDAQ and S &P 500 also dropping more than a percent. It got ugly just after 2 p.m. Minneapolis Fed President Neil Kashkari warning that if inflation continues to move sideways, it, quote, makes me wonder if we should cut rates at all this year.

1:13Adding to the concerns, rising tensions between Israel and Iran, which sent oil prices to their highest level since October. So could these two risks in tandem put a cap on market optimism, which has been fueling us higher this year? Well, 15 and a half hours, 830 tomorrow morning, the entire thing could change on a jobs number. So with that said, yeah, I believe so. And I think this today was sort of a continuation of March 8th. In fact, what are you talking about? The market didn't know the market didn't do anything on that Friday, March 8th. But the interday moves we saw in some of these names, specifically NVIDIA, to me, was really important.

1:48And quite frankly, NVIDIA has never recaptured the highs from that day. And a 250 million, excuse me, 250 billion dollar market cap swing that day alone in one stock, to me, sort of set things in motion. The VIX has been hanging around. Last couple of days, you've seen a move in the VIX. Obviously, today it moved significantly higher, but that's been telling you a story. And again, when you see a move of this magnitude intraday in the S &P, you have to take notice without question because you don't see it all that often. Yeah, but fascinating. Yields didn't move today. And that was the thing earlier in the week when we got stocks selling off a little bit.

2:20It was because that move in the 10-year yield kind of shot up. There was like two consecutive days of 10 basis points, which doesn't sound like a lot, but it's a lot in the 10-year yield that was trading at 415 or something like that. So I think all of us earlier in the week would have said, listen, if we have this continued move up to maybe four and a half or something like that, and that's kind of Guy's point. If we have a hot March jobs data tomorrow, we probably do have yields going up and then you probably have a continuation of the sell off in stocks. But, Mel, I can't believe what you just said.

2:48We have not had a down one point two or whatever percent day in over a year in the S &P 500. And remember, we had 11 percent peak to trough sell off from late July to late October. And that didn't incorporate more than a one and a half percent move. So we have been operating in a very low vol environment in the equity market. And at some point, there's going to be some a little bit of pain that needs to be felt, no matter how bullish you are about stocks near term. Totally agree with Dan, actually, on that. Actually, yeah. Congratulations. Should we take a pause? We got that going for us just one time.

3:20You know, I enjoyed this. A nice cooling off, a little bit of a correction. I think that's often good. I think what happened in Bonzo later today was the flight to quality somewhat. And so that's a bit noisy. But I think I guess what's the frothiest place out there is NVIDIA, I guess. So it makes sense to me that that would sell off. But even so, this isn't a – it hasn't been trounced completely. So I think if we do get in that really difficult environment, there's more to go in NVIDIA to the downside. Yeah, that idea that the big tech is is your place to be when times are tough. I don't know.

3:55Today we saw the Philly Semiconductor Index down three percent. We saw communication services down, information technology down. Those are the sectors that let us lower here. So it didn't come through here, at least today, especially when you have not just Kashkari sort of underscoring those concerns that maybe we won't get three. Maybe we'll get zero. And then you overlay with that the geopolitical tensions. Which, by the way, is a CIA warning that Iran could attack Israel in the next 48 hours. Well, yeah, and the geopolitics are really tough to handicap. But we talk about that on this desk, which is the dynamic here, that I think if we could just keep it contained, I think we could maybe start to make heads and tails out of at least trying to handicap certain events.

4:34But I think this was six Fed officials that followed after Powell yesterday who put the wheels in motion. I mean, he called out his crew and said, I need to reinforce a message. And I think the Fed recognizes. Let's not forget that the Fed targets financial conditions when they want them on the upside. They want to goose the wealth effect. They do it. They've done it before. And the flip side of that is the stock market's been out of control. So I thought the most interesting comments of the six that spoke today was probably, you know, Austin Goolsbee, who who tends to be, you know, pretty dovish.

5:06And yet got in there and said, you know, things look not too bad. I think, you know, these two inflation prints from January and February, not that big a deal. But if these housing numbers don't improve, we're never going to get to 2 percent. When I you know, you heard Meister, Meister, excuse me, who ultimately came in there and typically has been one to be more dovish, said I could wait a couple of months. That really means probably she could wait longer. And then, of course, Kashkari, who used to be the biggest dove out there now is the big hawk out there. So it's it's fascinating that the Fed and the conversation that not just us, a lot of people in the market have been having for a month is that maybe zero cuts.

5:41I think it's interesting yields can go lower before they could possibly even go higher. And at a day like today, the market thinks a couple steps ahead and says, look, if they're not going to do anything, we get it. We've got problems with inflation, but we will have problems with growth. Yeah, the market might take some solace in the fact that Kashkari, who couldn't have been more wrong a couple of years ago. So maybe he's equally wrong now. But we haven't. Well, I shouldn't say we haven't been a fan. I've been on record with all that said. Defense stocks, big day today. And look at the move in crude oil on top of the move that we've been seeing.

6:10So that's making the Fed's job more difficult. Throw on top of that the recent move in copper, some of the soft commodities that we've talked about. And then you have an understanding as to why it's very difficult to lower rates in this environment. And yields, to Karen's point, I think the reason why they did go down today was this perceived or the perception of a flight to quality. The bar is very high in terms of March. The inflation data for the month of March coming in better than January and February in that it should be lower. And now I don't know if we're going to see that, considering we had this sort of swing that there's no reason for it to come down at this point.

6:43Yeah, think about the last few years, though, some of the inputs or some of the causes of higher inflationary sort of things. Right. It has been geopolitical. Right. So we go back to early 2022. We go to some of the stuff that's going on in the Red Sea. So if there is some sort of situation and again, you know, it feels like we had not been talking about this irony and threat. You know what I mean? Especially as the war in Gaza kept on going and going. that sort of thing. I mean, anything that happens in reaction to that, save from the horrible human effects of that, is going to be inflationary for the globe.

7:10You know what I mean? Whether it's energy, whether it's food, whether it's, you know, that sort of thing. So to me, like that is that when we talked about this a little bit last night, it was like usually in these periods, right, when we come from these kind of rate hiking to pausing, and then when they start to cut, we go back, you know, to 2000, 2001, you go back to seven, eight, you go back to 2020. These are things that we could not have foreseen. And we know that there's plenty of geopolitical hotspots out there, but this would be a very different situation because in those prior three times, we were not dealing with inflationary pressures to the upside.

7:39If anything, they were to the downside. And that's what's different this time. Right. And then, of course, under all of this is if we do get embroiled somehow in some sort of conflict, is that even more reason for the Fed not to cut? Because you want to save some dry powder for a time when the economy might actually need it. I don't know. It's a very complicated sort of mosaic. Right. It is. I mean, well, particularly what Dan's saying is true. If we get mired in that and that causes additional inflation, then yes, why cut? And just to remind folks, and this isn't my political view, this isn't anything, but the fact is that the U.S.

8:13is taking a hotter line stance with Israel, that throws into question a lot of political kind of givens in the world and historically. And I think that's part of the volatility around this. So I look at also some of the relationships. Guy started to talk about the things that did well and things that didn't do well. As an energy investor, I don't love this kind of price action. OK, an energy actually XLE, which was cruising going into the morning, didn't really respond too well to this kind of news. So I don't think we love price spikes in the energy space. I think what we've liked are really the dynamics around some of the fundamentals in the sector.

8:44I do look at the broader market dynamics here and say, look, today was an interesting day. And we talk about the geopolitics. I think this was all about the Fed. and was today the day, because we've said this for a while. You think this move today was about the Fed? I think it was all about the Fed. I mean, we've had people coming out, Bostick yesterday, Gorman, I mean, a number, a number. Same zero or less than zero. Saying no cuts or one cut. But we had six Fed officials today who basically reiterated what Powell said yesterday. That's what I thought was more dovish. Well, look, what I'm going to tell you is I think we've questioned why equities haven't responded to the dynamic that actually there might not be rate cuts this year when, in fact, they priced in six or three or whatever.

9:22And at some point, equity markets have to respond. I think, I mean, I'm not making light of the geopolitics. I already brought it up. But I do think this was a broken record by the Fed today. But part of the conversation that we've had here is the answer to the question of what would the markets do if we said tomorrow that there would be no cuts? And we all said, not all, but many people said that the markets would do fine because that means that growth is actually intact. That story remains intact. So what is different today? If it's the Fed today, what is the difference between today and before?

9:53Because the Fed's data dependent, but they're not data dependent. They're kind of saying, we're going to wait either way. We're scared to death about, you said this yesterday, we can't cut too soon. I do agree with what Guy said, too. You're making a great point to remind us that we said a zero-cut environment means that the economy is better. But a zero-cut environment also means that the Fed is boxed into a corner, and we actually could have slower growth and stagflation. And that's what the market did today. Look what bond yields did and look what equities did. And that's stagflation. Yeah, I mean, historically, the cuts are because something's breaking, right?

10:24And the bulls will say they can cut this time because nothing's breaking. Things are moving along really nicely. And they can start to, I don't want to say normalize rates because I don't think lowering rates is anything near normal. But they can do that because there's nothing to stop them, right? The economy's doing well. Unemployment's under control, all those things. That's the best case scenario. But I don't think, see, that's the thing. I don't think that's what's going to happen. And if they lower rates, it's because something is breaking along the way. And you're starting to see, I don't know, signs of that today.

10:52And real quick in terms of energy, Tim makes a great point. If we have an XLE chart or an Exxon Mobil or Conoco, I mean, both these names, Exxon and Conoco, are right up against prior all-time highs. The laggard has been Chevron, which made its all-time high right around the time, if you recall, I think it was November of 22, when it announced a$75 billion stock buyback. That marked the top. But these stocks are right there. I think they're going to go through, but I can understand why you might want to take money off the table. All right, let's get more on the move. And oil prices, WTI trading above 86 bucks a barrel, Brent climbing above 90, both at their highest since October.

11:25For more on this, let's get to CNBC's Pippa Stevens. Pippa. I'm Vazra, Melissa. Brent settling above 90 for the first time since October as fears of a wider conflict in the Middle East spooks the oil market after Iran vowed retaliation following a missile strike on its consulate in Damascus. When asked earlier today if the CIA warned Israel about an Iranian plan to attack within 48 hours, National Security Council spokesperson John Kirby said, quote, they did talk about a very public and very viable real threat by Iran to Israel's security. BOK Financial's Dennis Kistler said the retaliatory actions will most likely involve the oil complex in some manner, whether it strikes against more Red Sea shipping lanes or directly on the Strait of Hormuz, which is adding fears that it will disrupt transportation of crude oil and oil products.

12:17Melissa? Any guesses at this point, Pip, on what the impact to Brent would be? I think at this point we have to see if any infrastructure is actually hit and the nature of any retaliatory actions. I think after Russia first invaded Ukraine, there was a lot of fear in the market that all of a sudden supplies would be disrupted, which is why we saw prices get above 130. That did not end up happening. So I think this time around there is more hesitation to jump fully in. But clearly the market right now is saying maybe this is a little bit more of an issue for oil than previously thought. All right.

12:50Pippa, thanks. Pippa Stevens, we were just talking about the spike in oil. We're better off just having a high level of oil and not a spike. And that's the points Tim making. I mean, I still think it's going to be I think it's going to wind up bullish for the energy complex and XLE. But I understand. And quickly, defense stocks, I mean, throw up a Lockheed Martin, for example. Good day today on the back of what's been a good couple of weeks. So I think defense stocks have been trying to tell you something along the way as well. So you're saying if tomorrow wake up and nothing's really happened, do you think then oil will retrace entirely?

13:19Or do you think there's going to be some level of elevated oil? I think oil wants to go to these levels. It's been on that trajectory for a while. It got sort of fast-tracked today. But I think whether it happened today or a week from now, two weeks from now, I think that's where we're going. Tim's point about, you know, this is not the environment where you want necessarily. But I understand that. But this rabbit's been out of the hat for a while. It's more that if you're investing in energy equities, you don't really like a spike in oil because it's never given the benefit of the doubt. And so energy equities, I think, have been moving higher on a combination of steady oil prices, you know, whatever you believe OPEC can and cannot do in terms of controlling supply.

13:57You believe that these companies are in a pretty good spot and that actually the biggest integrated oil companies for the last three years have been paying down debt and putting themselves in a very defensive position in terms of their dividends. All right. Meantime, Meta eking out a gain in spite of today's sell off. The stock hitting a record$530 during the session after catching three fresh analyst upgrades. Mizuho named me in a top pick for April while both RBC and Jeffries hiked their price targets. Jeffries saying it expects Meta to capture 50 percent of incremental ad dollars in 2024. That's well above the 33 percent it got in 2023.

14:29So very bullish here. We saw that it was up as much as, I think, four plus percent during the session, Karen. Yeah, I mean, I like that. That was that sort of the headline number of the piece. But also what it says is that that it so earnings will go up, of course, but then it has a 23 multiple, which is really not a very, you know, expensive multiple for a company like this. So that that was the base case, that 585 target. And in fact, they had a seven hundred and fifteen dollar bull case, the upside case, and I think three seventy five on the downside. But there's a lot to like there. And that didn't even include the cash.

15:04Yeah. You know, it's interesting. And this stock capped up 20 % after it reported its Q4 results and gave this guidance. And so here we are. We're trading at all-time highs. And again, I think the valuation story, I think what they've done, rationalizing costs, how they're using generative AI, all this stuff. It's all there. And it's cheap. I get it. I get it. I get it. But I just think it becomes incrementally that much harder to kind of surprise the way they did to the upside from an all-time high, near an all-time high last quarter. And the other side of this is like, you know, Alphabet's kind of stuck in the mud.

15:31You know, Alphabet hasn't had that moment. They've had two consecutive disappointing quarters, two disappointing guides, a couple disappointing launches of their generative AI or whatever. And so as high as the expectations are getting for Meta, they're getting very low for Alphabet. And that could set up really interesting as we get through, let's say, a couple rocky weeks of volatility possibly and get into earnings. Because to me, these could set up as decent pairs trades in the near term. Right. When you talk about Alphabet, it's because they're trying to sell basically an AI product. And Meta is just trying to benefit its business with AI.

16:02And that was which is working, which is working, right, which is working in terms of selling ads for reels. It's working for a lot of different things in Vantage Plus. And so that's that sort of thesis. So it's interesting to think about AI as a product. And some companies are benefiting from that. And then this is just the application of AI to one's business, which is probably what we're going to see a lot more for a lot of the other companies outside the mag. So, you know, Karen talks about this a lot when stocks should or shouldn't be at certain levels. So if you would take away that obviously huge drawdown in Facebook, most of it because of their own mistakes and just looked at this stock, you'd be like, it makes perfect sense that it's here.

16:37But we're looking at it through the context of this ridiculous run that it's had from the low. So it looks like parabolic move. But with that said, 21 times next year's numbers ish. Right. You're probably talking about, I don't know, 15 percent EPS growth, 12 percent revenue growth or so. And as Karen said, that's without the cash. So there's nothing not to like here other than the fact it's had this tremendous move higher. Yeah, it's interesting that we can say at 21, 22 times it's not expensive. It's not. But that didn't matter when it was 14 times. So, you know, it really just tells you that I think they're in the sweet spot in terms of where, first of all, this was a company that everybody knew about what the DAUs, the MAUs, whatever you're tracking, that this base of customers is so powerful.

17:19It's a cash flow machine. If they could ever decide just to be a company that wanted to generate free cash flow. Well, they said we're going to go out there and do it. And then they also had core businesses they were working on that really are benefiting from AI. I'll say this about Google. I mean, I look at that chart. There's nothing about that chart that bothers me at all. I still think Google is one of these names. I mean, it's been easy to malign them and it's understandable. But again, as they begin talking about pricing or not pricing, what AI could mean for their core business, I think they're catalysts there.

17:47Do you think that it's not good, that Meta is not going to do much better from here because of the run that it's had? No, I think you make a really good point. The way that they built this llama, this model, it's open source. There's going to be a lot of applications that are built in and around that, but that's something that is in the making here. What they're doing right now for their own ad product is the thing that I think has been realized. It's been realized in that guidance. So I don't really have a strong sense. I just think it's interesting that there was a few analysts out today, and they were talking the same way they were about Meta, and they were all kind of downbeat a little bit on Alphabet.

18:19And the one thing I'll just say is if Google were to do this deal that was rumored a couple weeks ago, something with Apple, you know what I mean? This could be a really interesting time at a really interesting valuation, at a really interesting sentiment level for this stock right here. So that's the way I'm thinking about it. I think Meta, if you're there, fantastic. If you're not in Alphabet, there might be an opportunity. But even if it gaps down on its third consecutive miss in Guide Down, it's probably not a bad do at that point also. Right. Coming up, the battle's been won, but now what?

18:49Disney CEO Bob Iger weighing in after coming out on top in the Nelson Peltz proxy battle. And now he's setting his sights on the media giant's next big hurdle. More on that next. And some stock moves catching our traders' eyes, a potential tech deal, a casino call, and a food processor plunging. We've got it all when Fast Money returns. This is Fast Money with Melissa Lee right here on CNBC.

19:21Welcome back to Fast Money. Disney CEO Bob Iger speaking exclusively to our David Faber after he won the months-long proxy battle with activist investor Nelson Peltz of Tryon Partners. He discussed what the company's priorities are now. Now what we have to do is turn it not just into a profitable business, into a growth business. A business that has margins that this company and our shareholders would really be proud of. Double-digit margins then, right? Eventually, yes, double-digit margins, of course. The way to do that is actually very, very clear to us. It's very, very clear that we need more engagement in terms of consumers spending time on the platform.

20:00But despite his loss yesterday, Peltz said he is not backing away from advocating for change at the media and entertainment giant. I hope Bob can keep his promises. I hope they can do all the things they assured us they were going to do. And we'll only watch and wait. If they do it, they won't hear from me again. If they don't, Jim, you may be seeing me on your show next year doing this same thing again. So can Disney succeed in its execution plans? I mean, he at least right now hopes so. He's got a three and a half billion dollar stake at last filing. Well, yes. And he's going to continue both because this is what he does for a living.

20:47He's got a lot on the line on this one. But any expectation that you're going to have a different outcome today, I think, was was was off base. I think this isn't a real surprise. It's also interesting to hear Bob Iger say, you know, now we have to do as if, you know, suddenly now that this is out of the way, you know, suddenly everything becomes a lot clearer. I think he said some of these messages, these messages have been said for months now in terms of costs and profitability dynamics. And I think that last quarter of earnings has as much to do about where the stock is than this proxy fight.

21:22Yeah, I think it was a great interview. I mean, David really pushed him hard and a lot of different things. One that I thought was interesting, it's not so newsy, but the idea that they hope to be number two in streaming. He didn't really say it like that, but that was sort of the way David framed it. And it's over. Right. Netflix has won. So they're hoping to be number two. You wouldn't think Bob Iger would say, if we're going to turn this around, we're going to make it be number two. Well, they're already, they're already. But don't they have a lot of other levers when you think about Netflix is trying to get into live, right?

21:50And they might be bidding for sports. And if you think about the thing that they're trying to fix and they're trying to monetize is that ESPN in a way. So to me, I think that like, it's kind of easy to just say, okay, we're number two. But at the end of the day, if he's successful in transforming this business and getting to some of those things, they're going to probably do something a little bit better, and they're going to be in a better spot than Netflix to kind of do something horizontally, in my opinion, on the streaming front. But again, and I'll just say this about the stock, you know, after that quarter that Tim just mentioned, the stock gap from 100 to 110, consolidated a little bit, this proxy fight started, it went to above 120 or so.

Read the full transcript

22:23If it were to come back, by the time you get to their earnings in early May, it could set up as a great thing. They're not going to lay an egg on that next quarter. Like, think about that, when Bob Iger's on that thing. So you almost last quarter was the one where they couldn't land it. Well, that one, too. But but but but right. I mean, he's got a little honeymoon period, a little coverage. But I'm just saying, like, if this thing were to come back in towards 110, then it sets up as a great entry point, in my opinion. The interesting day for me will be April 18th. So Netflix reports on the 18th.

22:49Stock has had a huge run. We've talked about as it gets towards 32, 33 times next year's numbers. Historically, that's when it starts getting expensive. And we're pretty close to that now. The prior all time high is probably another 50 dollars or so from here. So if Netflix stalls but Disney hangs in, that's a bit of a tell here. So I'm one of these people I think Tim might agree. I think you stay along Disney here and their earnings in early May. There's a lot more fast money to come. Here's what's coming up next. A potential tech deal, gambling on a casino stock, and a potato processor getting fried.

23:21How our traders are handling today's big moves and Wall Street calls. Plus, big hopes for small caps. Why our next guest sees a turnaround on the horizon and where you can set your sights within the space. You're watching Fast Money live from the Nasdaq market site in Times Square. We're back right after this.

23:49Welcome back to Fast Money Stocks, staging a late day sell-off on geopolitical tensions and rate cut concerns. The Dow dropping more than 500 points. It's now on pace for its worst weekly loss since March of last year. The S &P and Nasdaq both falling more than 1%. Meantime, shares of HubSpot jumping today after reports that Alphabet might make an offer on the online marketing software company, which had a market cap of about$31 billion as of yesterday's close. The potential deal would be Alphabet's largest ever. And shares of Lamb Weston having its worst day ever after the French fry maker missed on earnings and reduced its outlook, claiming weak snack demand.

24:25And Mizuho betting big on win. Analysts at the firm initiating the casino stock with a buy rating and slapping up the$131 price target on the name. 24 percent higher from current levels. The stock had been up nearly 4 percent at its highs, but closed down slightly. Well, I just thought I heard lamb was down 20 percent. And I thought and I said, why? And I said potatoes. French fries. I thought it was lamb research. I thought it really was like, what? L-O-C-X. No, no. L-W. Okay, I'm not so familiar with LW. I mean, a little more now. You make like the frozen French fries. Is it an exempt thing?

24:59Is that what's happening? I don't know. They said less of a demand for snacking, but it's been going on for some time, so I don't know if this is like a new thing or not. I'm not as well-versed in the snack area. You just pointed at me when you started talking about snacking. I know that you like to snack. I snack. I'm not afraid to snack. Sure. I mean, I'm not a French fries guy as much as like I'd go Cheetos right now. If you had a bag. If you waved a bag of those hot ones in front of me. The flame-in-ups? Flame, of course. Are those takis? Our friend Tillman, who might be watching the show.

25:29You know this. Of course. I mean, I think it was on our show that we – this is a while ago. His stake in when – remember, you recall. Yeah, yeah. We're actually going to talk about a real stock as opposed to snacking. Thank you. I'll talk about snacking if you want. No, no, no. Thank you for getting us back on track. Well, I'm known to do that from time to time. But look at this stock. This is the highest the stock's been, I think, since August. Yes, it sold off late in the day like everything else. But again, this is one I think you want to stay with it on alongside. They report, I think, on May 5th, 4th or so.

25:57Stay long wind for sure here, Melms. Chances Alphabet can buy a company that's worth$31 billion in market cap. Probably not great. More importantly, it's 13 times sales. Their sales are 10 % of that of Google's. Yeah, it's an 84 % gross margin business at HubSpot, but they still lose money on a gap basis. So to me, when you have to fix this generative AI thing and you're battling some absolute behemoths, whether it be Microsoft and Amazon and OpenAI and the list goes on and on, you've got to get this thing right. So this seems like it would be a distraction. And hopefully the market's speaking a little bit and helping them come to the conclusion that they shouldn't make this acquisition.

26:32Coming up, still hanging on to Macy's department store chain down four days in a row as store closures weigh on the stock. But one of our traders isn't letting go just yet. They'll explain why. And will we see a small cap comeback? Our next guest will lay out why he is seeing big things out of the group and the sectors that could lead the charge. Fast Money is back in two. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.

27:07Welcome back to Fast Money. It hasn't been all bad news for small cap stocks this year. Take a look at restaurants like Shake Shack, gaining 35 percent since January and newly public Kava. That's up nearly 50 percent. The names are among the favorites of our next guest who predicts a bigger recovery in small caps. Greg Torto is a small cap portfolio manager at Goldman Sachs Asset Management. He runs a firm small cap core equity ETF listed under ticker GSC. Greg, welcome to the show. Thanks for having me. Before we get to the picks, because we do want to get to them, in terms of the rate environment, what do small caps need at this point?

27:39You saw a little bit in the fourth quarter when the rates declined to in the 370s. You saw small caps respond very, very positively. I think other financial conditions have eased a bit, which is also helpful for small caps. And I do think that a little bit more rate clarity will be a nice tailwind for the group. We may not get that this week, but I think it's something that we should get more likely in the second quarter. OK, let's talk about what you like. And you like the consumer sector. You're all bulled up, you say, about the consumer. Why? What do you see that is so convincing to you that the consumers will continue to spend?

28:13I think the consumer has chosen very, very broadly with their feet in terms of how they spend their money. And you mentioned two of them. We like the restaurant theme a lot. Shake Shack and Kava are two of them, two companies that are really focused on not just menu but loyalty. And they're run by management teams that have been very, very efficient on the real estate side of things. Shake Shack has went through its own troubles before they kind of corrected themselves. And we think the new management team will be helpful there. But Kava has really learned from the mistakes of the past. And I think that that's one that's set up quite well for the future.

28:44Full disclosure, I worked at Shake Shack. I have to say that, right? That's true. And we've been collectively bullish. But how do you wrap your head around valuation? Because it is not a cheap stock at these levels. You know, I think that there's a bit of under earnings, you know, in what's gone on there. And I think that what you'll see as we move forward is a bit bigger ticket. And I think you're going to get a little bit more on the growth side in terms of units that are out there. I think that they're a bit behind the curve on units as they're waited for the management change to go through.

29:10So it's on present numbers. It's not it's not cheap at all. But I do think if you can you look at two years and you start to see something more aligned with the growth rate that we that we that we're looking for. Greg, we obviously spent a lot of time talking about debating, as everyone is right now, about inflation, inflationary inputs and the like here. When you think about your sector, they're obviously, you know, a bit more sensitive, let's say, to larger cap stocks, especially with higher rate environment and the like here. What do you what's your outlook right here? And obviously you pick small caps.

29:37You put them in your ETF here. We spent a lot of time looking at the Russell 2000, which is 2 ,000 stocks here. But are you optimistic about a broader swath of stocks rather than the ones you're just looking at? Yeah, I think that what we try to look at is within the Russell 2000, you have a lot of stuff that you probably don't want to own. There's a significant amount of unprofitable companies. You had a large number of SPACs in there for a long period of time. That's starting to slowly drift away. You have a lot of rate-sensitive companies that we don't really kind of get into in the REITs and the utilities and things like that.

30:06So if you look at some of the names that not necessarily are at the largest part of the benchmark, but in the sort of that$2 to$5 billion range where you can find some of the companies can make their own weather. You mentioned consumer. We like the semiconductor space a lot. I do think that some of the areas in health care, some medtech names that we like. These are companies that have gone through an earnings recovery that started to go down two years ago before the large cap guys. So I think that these companies can respond favorably, you know, as some of the tailwinds and headwinds balance out a little bit more.

30:39But I do think that you have to be very selective in small caps because things can go down with great velocity. In semiconductors, do you need to see the NVIDIA story slow down in order for that specific subsector to do well? I mean, are these, you know, AI sort of semiconductor stocks or AI adjacent? AI adjacent, I'd say. I think that some of the companies we own, there's a company that went public a few weeks ago called Astera Labs that we invested in. We knew the company, you know, for a couple of years before they went public, so we were eager to invest in that one. And then other companies like Kohu and Onto Innovation, we think can benefit from just a large recovery in chips and things like high bandwidth memory, which is an analog to NVIDIA's growth.

31:17You need that high bandwidth memory to make those AI machines hum. Greg, thanks for stopping by. Thanks for having me. Greg Torto, Goldman Sachs Asset Management. Karen, where are you in small caps? Well, I like them, and I've been surprised that they haven't done better, right? There was that, I don't know, false dawn. Maybe it's still somewhat dawnish, but Shake Shack is interesting. Kava is also interesting. Crazy, great management team. Great, I mean, Ron Shake is, you know, big holder and the chair of the board. But, oh, my God, are these stocks expensive. Red Dawn was a great movie. It was unbelievable.

31:49Howard Booth, Leah Thompson. No, it was a tremendous movie. Okay, I'm sorry. Small caps. So I've gone out there and said, and first of all, Greg and the team, they do great work. So I just point out that a lot of times I feel like we pay more attention to small caps than we should in an environment where I think actually there is some question about growth. And so I've also mentioned that I believe sometimes small caps are a great hedge in a world where you actually think growth is under some question. And I've used that IWM on the short side in a world where I think we're worried about macro.

32:22I know we've got to go. But you're going to say it anyway. You're going to laugh while you say it. No, but to Tim's point, I'll take Swayze, Jennifer Grey, and Red Dawn over Swayze, Jennifer Grey, and Dirty Dancing every day of the week. I forgot about Jennifer Grey in there, too. Red Dawn. Swayze's a legend. But Leah Thompson. Underrated. What you're really talking about. It's going to go to break. Coming up, a department store downer. Macy's dropping nearly 8 % this week. But one of our traders is still holding on while they are betting this name can still turn things around. next. Plus, can GLP-1 drugs treat Parkinson's?

32:55New clinical trials suggest it is possible. Dr. Kavita Patel will join us to break down a surprising new study that could help shape the future of the space.

33:09Welcome back to Fast Money. Macy's shares dropping for the fourth straight day, now down nearly 8 % just this week. It's on pace for its worst week since November. The department store chain is also set to close more than a quarter of its 500 stores across the U.S. Despite the problems and the price action, one of our traders is still long, this retailer. So, Karen, what's the bull case here? Well, the bull case is the pressure has been ratcheted up. So two days ago, Arkhouse, which we know has been trying to become, they finally signed an agreement allegedly to allow them due diligence. And it's going more slowly.

33:43And we thought we have a quote here from their proxy fight. But it's basically saying it's taken months of public advocacy and the launch of a proxy contest to replace the majority of the board to motivate the company to do the right thing. So they're really putting pressure on the board. Another interesting thing in this filing was they have to show what purchases they've made. And they made three big purchases right before they signed the confidentiality. So at prices as high as 2134, something like that, a fair amount of shares. So they really believe as recently as that, March 19th or whenever that purchase was, March 15th, that there was upside there even above that level.

34:19Macy's now needs to respond. They're in a full on proxy fight now. They could lose. They could lose control of the board. Wow. Guy, you're pointing this out, too. Well, I mean, the risk arbitrageurs out there like Karen, I mean, they have a field day with stuff like this. And just in risk reward, I think. But I would have said this at$20 to be clear. From the long side, I think you can play Macy's here. It's not just Macy's. I mean, Nordstrom's has a similar thing going on as well. So these companies are in play. So I think if you have some risk appetite, Macy's at 18 and a half bucks looks pretty interesting.

34:51I would have thought the same thing at 20. I did think the same thing. Without the activist overlay, would the Macy's story in and of itself be attractive? Probably not. But what's the downside, right? The question is downside versus up. Let's say it's 16. 16 versus 24 or more. That was their latest bid. Well, Macy's could respond by, you know, we're up for sale. Coming up, shares of Novo Nordisk and Eli Lilly have been surging on the strength of the GLP drug one, GLP one drugs. Could another potential use for these treatments give them an even bigger boost? We'll debate that. And here's a sneak peek at the Kramer cam.

35:24Jim is chatting exclusively with the CEO of ConAgra. Catch the full interview at the top of the hour on Mad Money. Meantime, more Fast Money in two.

35:36Welcome back to Fast Money, a promising sign that GLP-1s may be used to slow down neurological diseases. A new phase two study published yesterday found that participants with early Parkinson's disease taking the GLP-1 adlixin therapy had less motor disability than those using a placebo. There were, however, some gastrointestinal side effects. For more on this study, let's bring in Dr. Kavita Patel. She's the NBC News medical contributor. Dr. Patel, Great to see you. Thanks so much, Melissa. It is an interesting study. Yeah. Lixacenatide, which is the active ingredient in this particular drug, it's actually discontinued in the United States.

36:12Right. And so I'm wondering how it is a daily injection or it was a daily injection. And that's what they did in the study. Can we extrapolate these results to the GLP-1 drugs that are marketed today by Novo and Eli Lilly? Yeah, I think it's an important kind of precedent that we need to watch because we're seeing this not just in Parkinson's, but also a lot of the other diseases that you and I and the team have spoken about, cardiometabolic diseases in general. So I do think that this opens the door for thinking about linkages to neurodegenerative diseases like Parkinson's. And here's why. I think this is the disconnect that most people don't realize, that we know that there's a relationship between people who are diagnosed with diabetes and the propensity to demonstrate Parkinson's or Parkinson-like symptoms.

36:56So, Melissa, we know that there's some biologic relationship between that kind of insulin metabolic axis, and that's why GLP-1s can be very important. So while Adelixin did not make the cut for being kind of competitive on that weight loss and diabetes race with GLP-1s, that kind of mechanism of function in Parkinson's and this early promising data, remember, it's not reversing Parkinson's. And so we're not trying to make the promises that it does with weight loss or changing the nature of diabetes. But even slowing down these symptoms for 12 months, that can be incredibly valuable to quality of life.

37:30And I do think that this has implications for Novo, for Lilly, and even for some of the other GLPs that we've been talking about, the oral ones, some of the other drugs that are in the making from the pipeline. Does this sort of revitalize the possibilities for Lixin in that, you know, it was taken off the mark because it was not competitive. And now if this is actually an application, all of a sudden it's it's the Parkinson's drug. Yeah, it is a really important application. I'm very eager. Look, you don't get an often what we call a New England Journal medicine, high rigor, kind of a high bar that they set for the evidence threshold.

38:03So this met a number of those evidence thresholds and the scientific criteria from like the data safety monitoring board. So this gets not only kind of a green flag, but it points to what I think we've been talking about, whether it's liver disease, whether it's cardiac disease, which is why Medicare plans are covering the GLP-1 space. I feel like we're just still in this renaissance area. Is this going to be the fix it for all of these things? Not at all. But again, quality of life, much like we've talked about with other degenerative diseases like Alzheimer's. Unless if you're talking to someone that has Parkinson's like I have, and you can talk about slowing these symptoms down at least 12 months, that's an incredible amount of quality of life for them.

38:42So this is we're learning more about this axis of metabolism and all the parts of our body in ways that I had not even had access to in medical school. Dr. Patel, it's Karen. Thanks for being on. So for these Parkinson's patients, how far along were they? What were these early symptoms or more later symptoms? No, these were earlier symptoms. So this is definitely, I think, Karen, you're pointing out some very good caveats that this is not necessarily. I think a lot of us are very familiar with probably a lot of kind of higher profile celebrities. Michael J. Fox. There's a number of people with Parkinson's that we know in the public sphere at different degrees.

39:20These were earlier stage. So this is not late stage Parkinson's. And this was really looking at slowing down their symptoms. Again, not a reversal of Parkinson's. I think we still have to kind of caveat that, Karen. So I think it's one of these, it passed that threshold so that we saw clinical benefit. And I think going further, it's that question of now could this be used as a primary indication for Parkinson's, which is what I would expect the company to seek. Is there anything out of the study that would make you cautious? You know, the safety profile is good. I mean, that's a drug that's been on the market for a long time.

39:51But it seemed that there were a high percentage of gastrointestinal effects, side effects, nausea, for instance. And if that makes the bar even higher for, you know, to tell a patient, yeah, you can take this drug for 12 months and you can have a slowdown in disability, but you'll be nauseous. You have a 40 percent chance of being nauseous. Yeah, I do think that those side effect profiles. And by the way, this is what the critics of the GLP-1 space have said, that were even critics that you've talked to them, Melissa, that I think people have kind of glossed over these side effects. They are not trivial.

40:20When they do happen, they are serious and can be debilitating enough where people might say, I don't want those side effects. I'm willing to deal with the other side effects of my disease to not have the nausea. So I do. That does cause me pause. I wouldn't paint this as you should take this. This is so much better. The side effects are not that bad. People are overplaying them. And I think we've talked, Melissa, about extreme cases where you can see death and severe kind of GI distress so that this is not something that I would do lightly. Usually people with Parkinson's, and going to Karen's point, kind of people at later stage Parkinson's can have other GI effects.

40:55So I think that's why you're seeing maybe a perhaps more pronounced effect in those patients. So this will be meant for a very specific patient profile. Even though Parkinson's affects many people, it's not going to be for everybody for that reason. Dr. Patel, thanks so much for joining us. Good to see you. Thanks. Thank you, Patel. Another application here for this quote-unquote miracle drug. Which is remarkable. I mean, Karen, I mean, she's you've been on the board for how long, Michael J. Fox. So it's remarkable without question. I mean, and the indications continue to come, which is great.

41:25But the questions I think we have collectively is at what point for Lilly, for example, is the valuation just too stretched in this environment? That's the question you have to ask in earnings at the end of the month. The other dynamic here is is where you bring in more Medicare coverage. And so you have a dime. You know, it just may be a way that the addressable market meets the insurance payment market in a place where the drug companies really have a bigger struggle on their hands. Because, again, the pricing here may be challenging. Up next, final trades.

42:01Final trade time, Tim. Yeah, I like those upgrades. And when another place that has a lot of exposure to Macau, Las Vegas Sands, I still think that whole space, especially with Macau exposure, is very cheap. Karen? Yes, I agree with Dan a few times tonight. What? Actually, several. Mark the date. Yes, alphabet. Dan. O-O-G kind. And I agree with Tim and Guy about Disney. I just think under any circumstance, the stock sells off into that print in early May, I think you'll find it. NBC page program, amazing. Our page, Chloe. Currently, yes, Chloe. It's her birthday, so we've got to give her. Happy birthday, Chloe.

42:37Look at that. 23, I'm unbelievable. American Barrack, that comes out gold, Milms. All right. Thanks for watching Fast Money. Mad Money with Jim Cramer starts right now.

42:53All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:27To view the full Fast Money Disclaimer, please visit CNBC.com forward slash Fast Money Disclaimer.

From the publisher

Stocks reversing course as investors fear it could take the Fed even longer to cut rates. So could a potential delay keep markets from continuing their climb? Plus… is there a small cap comeback on the horizon? The signs starting to emerge, and where you look for leadership in the space.

 

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Markets Big Reversal… And A Potential Small Cap Comeback 4/4/24CNBC's "Fast Money" · 44 min
Listen in VO